This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Globus Medical Reports 2013 Third Quarter Results

Stocks in this article: GMED

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the quarter ended September 30, 2013.

  • Worldwide sales were $107.2 million, a 13.1% increase from the third quarter of 2012
  • Net income was $20.3 million or $0.22 per diluted share
  • Non-GAAP Adjusted EBITDA was 33.4% of sales

“We are very pleased with our industry leading top line growth and profitability this quarter. Our growth this quarter is again attributable to the increased adoption and success of newer, more disruptive products, which are designed to provide better treatment for the patient, and are safer and easier to use for the surgeon,” commented David Paul, Chairman and CEO. “During the quarter we launched CREO™, our next generation pedicle screw platform, one of the most significant projects in our history. CREO™ offers surgeons significant intraoperative adaptability to tailor the construct to best meet individual patients’ needs in treating complex spinal pathologies.”

Mr. Paul continued, “This quarter, we also continued our trend from the first half of the year in attracting and retaining key sales force talent. Our excellent product development execution and robust sales force expansion have us well positioned to continue to take share in the spine market into 2014 and beyond.”

Third quarter net sales were $107.2 million, compared to $94.8 million last year, representing a 13.1% increase. US and international sales grew by 12.6% and 19.1%, respectively, over the same quarter in 2012. International sales represented 8.5% of worldwide third quarter sales.

Net income for the quarter was $20.3 million, or $0.22 per diluted share, as compared to $16.5 million, or $0.18 per diluted share, for the third quarter of 2012. Non-GAAP Adjusted EBITDA for the quarter was 33.4% of net sales, compared to 35.1% for the same period last year. The Medical Device Excise Tax, which was not in effect in 2012, reduced Adjusted EBITDA by 1.8% for the third quarter of 2013.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,688.55 +331.68 1.91%
S&P 500 2,046.83 +33.94 1.69%
NASDAQ 4,723.6640 +79.3520 1.71%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs